In a clinical trial, RA patients on sirukumab experienced decreased disease activity and improved physical function…
When Starting Biologics for RA, Disease Severity Predicts Likelihood of Remission
NEW YORK (Reuters Health)—After starting biologic therapy for rheumatoid arthritis (RA), patients with higher disease activity at baseline achieved greater improvements in measures of disease activity than those with lower levels of disease, but they were less likely to achieve remission or even low disease activity, according to a new real world analysis of registry data….
Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA
In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…
Sarcoidosis: Insights into the Targets of Cellular Immunity
Stimulation with both Kveim reagent and vimentin induces a specific pro-inflammatory cytokine secretion from sarcoidosis PBMCs. Further investigation may identify novel biomarkers to assist the diagnosis of sarcoidosis…
Comparative Assessment of the Different ACR/EULAR Remission Definitions for RA for Their Use as Clinical Trial End Points
Significant advances have been made in the treatment of RA over the past 20 years, and with the hope of developing even more effective therapeutics, achieving a very low level of disease activity, such as remission, is an important outcome to be examined. The ACR and EULAR have defined remission using Boolean- or index-based criteria. The researchers undertook this study to compare definitions of remission to inform choice of end points for future RA clinical trials and included in their comparison the remission criterion of a score of ≤2.8 on the Clinical Disease Activity Index…
Peripheral Helper Cells May Provide Clue to RA Pathology
Research has identified a subset of T cells, peripheral helper (TPH) cells, which may promote pathological B cell responses and antibody production in patients with seropositive RA. TPH cells also express chemokine receptors, enabling them to infiltrate inflamed parts of the body and stimulate B cells to produce antibodies…
Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients
In patients with RA, age and higher rates of comorbidity are influential in selecting and changing treatments…
Denosumab Does Not Increase Risk of Infection in RA Patients
New research dispels the fear that denosumab will increase the risk of infection in vulnerable populations with rheumatoid arthritis when it is prescribed in combination with TNF inhibitors or other biologics. Investigators found the treatment did not increase infection risk beyond what is expected for the patients’ disease, comorbidities and medications…
RA Treatment Options: Researchers Explore Groundwork for New Therapies
WASHINGTON, D.C.—Researchers at the 2016 ACR/ARHP Annual Meeting discussed how they are exploring the immune system in search of groundwork for new rheumatoid arthritis (RA) treatments. The new avenues, supported by the Rheumatology Research Foundation, involve T cell adhesion, new understanding of the role of macrophages and insights into the way IgG glycans function. T…
Disease Trends in Hispanic RA Patients in the U.S.
As the Hispanic population has grown in the U.S., very little research has examined the potentially unique clinical features of rheumatoid arthritis in these patients. A new small-scale study of Hispanic patients with RA identified trends in functional disability—showing that disease activity, pain and depression were modifiable parameters over time, with consistent, independent and additive contributions to changes in functional disability across the disease trajectory…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 30
- Next Page »